VP7 of group A rotavirus(RVA) contains major neutralizing epitopes. Using the antigenic protein VP6 as the vector, chimeric proteins carrying foreign epitopes have been shown to possess good immunoreactivity and immun...VP7 of group A rotavirus(RVA) contains major neutralizing epitopes. Using the antigenic protein VP6 as the vector, chimeric proteins carrying foreign epitopes have been shown to possess good immunoreactivity and immunogenicity. In the present study, using modified VP6 as the vector,three chimeric proteins carrying epitopes derived from VP7 of RVA were constructed. The results showed that the chimeric proteins reacted with anti-VP6 and with SA11 and Wa virus strains.Antibodies from guinea pigs inoculated with the chimeric proteins recognized VP6 and VP7 of RVA and protected mammalian cells from SA11 and Wa infection in vitro. The neutralizing activities of the antibodies against the chimeric proteins were significantly higher than those against the vector protein VP6 F. Thus, development of chimeric vaccines carrying VP7 epitopes using VP6 as a vector could be a promising alternative to enhance immunization against RVAs.展开更多
The comparison between traditional Chinese medicine Jinzhen oral liquid(JZOL)and West-ern medicine in treating children with acute bronchitis(AB)showed encouraging outcomes.This trial eval-uated the efficacy and safet...The comparison between traditional Chinese medicine Jinzhen oral liquid(JZOL)and West-ern medicine in treating children with acute bronchitis(AB)showed encouraging outcomes.This trial eval-uated the efficacy and safety of the JZOL for improving cough and expectoration in children with AB.480 children were randomly assigned to take JZOL or ambroxol hydrochloride and clenbuterol hydrochloride oral solution for 7 days.The primary outcome was time-to-cough resolution.The median time-to-cough resolution in both groups was 5.0 days and the antitussive onset median time was only 1 day.This random-ized controlled trial showed that JZOL was not inferior to cough suppressant and phlegm resolving western medicine in treating cough and sputum and could comprehensively treat respiratory and systemic discom-fort symptoms.Combined with clinical trials,the mechanism of JZOL against AB was uncovered by network target analysis,it was found that the pathways in TRP channels like IL-1b/IL1R/TRPV1/TRPA1,NGF/TrkA/TRPV1/TRPA1,and PGE2/EP/PKA/TRPV1/TRPA1 might play important roles.Animal ex-periments further confirmed that inflammation and the immune regulatory effect of JZOL in the treatment of AB were of vital importance and TRP channels were the key mechanism of action.展开更多
基金supported in part by the Foundation of the Applied Basic Research Project of Yunnan Province,2013FZ130the Foundation of the Applied Basic Research Project of Yunnan Province Youth Program,2012FD039
文摘VP7 of group A rotavirus(RVA) contains major neutralizing epitopes. Using the antigenic protein VP6 as the vector, chimeric proteins carrying foreign epitopes have been shown to possess good immunoreactivity and immunogenicity. In the present study, using modified VP6 as the vector,three chimeric proteins carrying epitopes derived from VP7 of RVA were constructed. The results showed that the chimeric proteins reacted with anti-VP6 and with SA11 and Wa virus strains.Antibodies from guinea pigs inoculated with the chimeric proteins recognized VP6 and VP7 of RVA and protected mammalian cells from SA11 and Wa infection in vitro. The neutralizing activities of the antibodies against the chimeric proteins were significantly higher than those against the vector protein VP6 F. Thus, development of chimeric vaccines carrying VP7 epitopes using VP6 as a vector could be a promising alternative to enhance immunization against RVAs.
基金the National Key Research and Development Program of the Ministry of Science and Technology of China in 2018,“Research on Modernization of TCM”project,“Demonstration Study on Evidence-based Evaluation and Effect Mechanism of Ten Chinese Patent Medicines and Classic Famous Prescriptions in the Treatment of Major Diseases after marketed”(2018YFC1707400 and 2018YFC17074101,China)National Administration of Traditional Chinese Medicine(GZY-KJS-2024-03,China).
文摘The comparison between traditional Chinese medicine Jinzhen oral liquid(JZOL)and West-ern medicine in treating children with acute bronchitis(AB)showed encouraging outcomes.This trial eval-uated the efficacy and safety of the JZOL for improving cough and expectoration in children with AB.480 children were randomly assigned to take JZOL or ambroxol hydrochloride and clenbuterol hydrochloride oral solution for 7 days.The primary outcome was time-to-cough resolution.The median time-to-cough resolution in both groups was 5.0 days and the antitussive onset median time was only 1 day.This random-ized controlled trial showed that JZOL was not inferior to cough suppressant and phlegm resolving western medicine in treating cough and sputum and could comprehensively treat respiratory and systemic discom-fort symptoms.Combined with clinical trials,the mechanism of JZOL against AB was uncovered by network target analysis,it was found that the pathways in TRP channels like IL-1b/IL1R/TRPV1/TRPA1,NGF/TrkA/TRPV1/TRPA1,and PGE2/EP/PKA/TRPV1/TRPA1 might play important roles.Animal ex-periments further confirmed that inflammation and the immune regulatory effect of JZOL in the treatment of AB were of vital importance and TRP channels were the key mechanism of action.
